Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World

PURPOSE: To evaluate the efficacy and safety of lenvatinib combined with programmed death receptor-1 signaling inhibitors plus transarterial chemoembolization (LePD1-TACE) for treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting in China. METHODS: This was a retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaowei, Fu, Zhigang, Chen, Xiaoxia, Cao, Kunkun, Zhong, Jiaming, Liu, Li, Ding, Ning, Zhang, Xiaoli, Zhai, Jian, Qu, Zengqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289205/
https://www.ncbi.nlm.nih.gov/pubmed/35860582
http://dx.doi.org/10.3389/fonc.2022.950266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289205/
https://www.ncbi.nlm.nih.gov/pubmed/35860582
http://dx.doi.org/10.3389/fonc.2022.950266

Ejemplares similares